All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
DUBLIN – Genmab A/S's Duobody bispecific antibody technology received a stamp of approval from the big Kahuna of Danish biopharmas, Novo Nordisk A/S, which is in-licensing two programs that address two different target combinations, in a deal potentially worth up to $500 million in development, regulatory and sales milestones, as well as $2 million up front.